Respiratory effects of treatment with a glucagon-like peptide-1 receptor agonist in patients suffering from obesity and chronic obstructive pulmonary disease
It lowers blood sugar by improving insulin sensitivity, decreasing the amount of blood sugar the liver produces, and reducing the amount of sugar the digestive system absorbs
Further, GLP-1RA therapy was associated with reduced risks of stroke or TIA, MI, VTE, PE, all-cause mortality, hospitalization, and ED visits in participants with T2D
Tran said there was also no muscle loss observed with NA-931 in the trial
M.SchmelzerL.BraunL.MirandaC
When Ozempic or Wegovy shots seem out of reach, weve got you covered with affordable options